Chemomab Therapeutics Ltd
CMMB
查看詳細走勢圖
1.890USD
-0.030-1.56%
收盤 12/19, 16:00（美東）報價延遲15分鐘
46.53M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-1.56%
5天
-14.86%
1月
-22.22%
6月
-60.63%
今年開始到現在
-73.90%
1年
-71.88%
查看詳細走勢圖
TradingKey Chemomab Therapeutics Ltd股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值低估，機構持股佔比非常高，近一個月多位分析師給出公司評級為強力買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Chemomab Therapeutics Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
2
分析師
強力買入
評級
26.500
目標均價
+867.15%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Chemomab Therapeutics Ltd亮點
亮點風險
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
估值高估
公司最新PE估值-1.57，處於3年歷史高位
機構加倉
最新機構持股1.06M股，環比增加8.03%
Chemomab Therapeutics Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Chemomab Therapeutics Ltd簡介
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
公司代碼CMMB
公司Chemomab Therapeutics Ltd
CEOMor (Adi)
網址https://www.chemomab.com/
常見問題
Chemomab Therapeutics Ltd(CMMB)的當前股價是多少？
Chemomab Therapeutics Ltd(CMMB)的當前股價是 1.890。
Chemomab Therapeutics Ltd 的股票代碼是什麼？
Chemomab Therapeutics Ltd的股票代碼是CMMB。
Chemomab Therapeutics Ltd股票的52週最高點是多少？
Chemomab Therapeutics Ltd股票的52週最高點是9.840。
Chemomab Therapeutics Ltd股票的52週最低點是多少？
Chemomab Therapeutics Ltd股票的52週最低點是1.910。
Chemomab Therapeutics Ltd的市值是多少？
Chemomab Therapeutics Ltd的市值是46.53M。
Chemomab Therapeutics Ltd的淨利潤是多少？
Chemomab Therapeutics Ltd的淨利潤為-13.95M。
現在Chemomab Therapeutics Ltd(CMMB)的股票是買入、持有還是賣出？
根據分析師評級，Chemomab Therapeutics Ltd(CMMB)的總體評級為--，目標價格為26.500。
Chemomab Therapeutics Ltd(CMMB)股票的每股收益（EPS TTM）是多少
Chemomab Therapeutics Ltd(CMMB)股票的每股收益（EPS TTM）是-0.547。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
